Key Takeaways
- Novo Nordisk (NVO) has introduced a new, tiered pricing structure for its oral Wegovy medication in the U.S., offering lower doses (1.5mg and 4mg) at $149/month and higher doses (9mg and 25mg) at $299/month for self-pay patients, effective January 5, 2026.
- Hon Hai Precision Industry (2317.TW), also known as Foxconn, reported robust Q4 sales growth of 22.1% year-over-year, reaching NT$2.6 trillion, with December sales surging 31.8% year-over-year to NT$862.82 billion.
- Major European stock markets opened positively, with France's CAC 40 and Germany's DAX each gaining 0.5%, while Britain's FTSE 100 and Spain's IBEX 35 both rose 0.4%.
- Spain's unemployment decreased by 16,300 in December, a smaller reduction compared to the previous month, alongside a net employment increase of 33,100 month-over-month.
Major financial news today includes a significant pricing update from Novo Nordisk (NVO) for its popular weight-loss drug, Wegovy, alongside impressive quarterly and monthly sales figures from tech giant Hon Hai Precision Industry (2317.TW). European markets are also showing positive momentum, while Spain's latest unemployment data indicates a continued, albeit slower, improvement in its labor market.
Novo Nordisk Unveils Tiered Wegovy Pricing for Self-Pay Patients
Pharmaceutical powerhouse Novo Nordisk (NVO) has announced a new tiered pricing model for self-pay patients in the United States seeking its oral GLP-1 medication, Wegovy, effective January 5, 2026. Lower doses of the Wegovy pill, specifically 1.5 mg and 4 mg, will now be available at $149 per month. This introductory price for the 4 mg dose is available until April 15, 2026, after which it will increase to $199 per month.
For patients requiring higher doses, the 9 mg and 25 mg Wegovy pills will be offered at a monthly cost of $299. This strategic pricing aims to enhance accessibility for self-paying individuals, potentially broadening the market for the highly sought-after weight-loss treatment. The company previously made commitments to lower prices for GLP-1s for self-paying patients.
Hon Hai Reports Robust Q4 and December Sales Growth
Hon Hai Precision Industry (2317.TW), commonly known as Foxconn, has disclosed strong financial performance for the fourth quarter and December. The Taiwanese electronics manufacturing giant reported a 22.1% year-over-year increase in Q4 sales, reaching a substantial NT$2.6 trillion.
The robust quarterly performance was underpinned by exceptional December sales, which surged 31.8% year-over-year to NT$862.82 billion. These figures highlight continued strong demand for Hon Hai's manufacturing services, particularly in its key technology product segments.
European Markets Open Higher
Major European stock indices began the trading day on a positive note. France's CAC 40 and Germany's DAX both advanced by 0.5%. Similarly, Britain's FTSE 100 and Spain's IBEX 35 each saw gains of 0.4%. The broad-based gains suggest a positive investor sentiment across the continent, potentially influenced by global economic outlooks or specific regional factors.
Spain's Unemployment Continues to Decline in December
Spain's labor market showed further improvement in December, with the number of unemployed individuals decreasing by 16,300. This marks a continued reduction in joblessness, although the decline was less pronounced than the previous month's figure of -18,800.
Concurrently, the country also recorded a net increase in employment of 33,100 month-over-month. While the pace of improvement has slowed slightly, the consistent reduction in unemployment and growth in employment indicate ongoing recovery in the Spanish economy.
Ed Liston is a senior contributing editor at TheStockMarketWatch.com. An active market watcher and investor, Ed guides an independent team of experienced analysts and writes for multiple stock trader publications.